Watch out AbbVie and J&J, AstraZeneca just took another big swing at one of your star cancer drug franchises
AstraZeneca reported Tuesday that its BTK contender Calquence (acalabrutinib) aced a Phase III trial as a second-line therapy for chronic lymphocytic leukemia patients, allowing researchers to call it early as they position this drug for greener pastures.
We won’t get the data until later in the year, but the UK pharma giant $AZN says they nailed statistically significant results on progression-free survival compared to a control group getting a combo of rituximab plus physician’s choice of idelalisib or bendamustine. And José Baselga, the company’s oncology research chief, says this is the first time a monotherapy has proven superior to a standard of care in this segment of the population.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.